On April 21, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled "Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis," will be presented in a poster session focused on Symptom Science and Palliative Care.

Presentation Details:

Session Type: Poster Session – Symptom Science and Palliative Care
Presentation Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT
Location: Poster Board #8
The abstract presents a pooled analysis evaluating the cardiac safety profile of annamycin in patients with high cumulative exposure to anthracyclines, an important consideration given the known risk of cardiotoxicity associated with this class of chemotherapeutic agents.

"We are pleased to have this abstract accepted for presentation at ASCO (Free ASCO Whitepaper), one of the most prestigious oncology conferences globally," said Walter Klemp, Chairman and CEO of Moleculin. "These data further support the potential of annamycin as a differentiated anthracycline with a favorable cardiac safety profile, even at higher cumulative exposure levels. We look forward to sharing these findings with the oncology community."

The ASCO (Free ASCO Whitepaper) Annual Meeting is one of the largest and most influential gatherings of oncology professionals worldwide, featuring cutting-edge research and advances in cancer treatment. For more information, please visit asco.org.

(Press release, Moleculin, APR 21, 2026, View Source [SID1234664616])

On April 21, 2026 ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, reported that results from its Phase 2 clinical study of VT-EBV-N have been selected for an oral presentation at the ASCO (Free ASCO Whitepaper) Annual Meeting 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ASCO (Free ASCO Whitepaper) Annual Meeting, to be held from May 29 to June 2, 2026 in Chicago, Illinois, is one of the world’s largest and most influential oncology conferences, where cutting-edge clinical data are presented and discussed among oncology experts. Among the thousands of abstracts submitted each year, only a limited number are selected for oral presentation, representing a highly selective subset of accepted submissions.

The presentation will be delivered by Dr. Young-Woo Jeon of Yeouido St. Mary’s Hospital, who served as the principal investigator of the study.

VT-EBV-N is an Epstein-Barr virus (EBV)-specific T cell therapy being developed for the treatment of NK/T-cell lymphoma, a rare and aggressive malignancy with a high risk of relapse.

According to the company, the Phase 2 study demonstrated clinically meaningful outcomes, supporting the potential of VT-EBV-N as a differentiated therapeutic option in this setting. Detailed results will be presented during the official session at ASCO (Free ASCO Whitepaper) 2026.

"Being selected for an oral presentation at ASCO (Free ASCO Whitepaper) highlights the clinical strength and growing momentum of our program," said Pyung-Suk Ki, Chief Executive Officer of ViGenCell. "We look forward to sharing the full data with the global oncology community and further accelerating our global development and partnering efforts."

About VT-EBV-N

VT-EBV-N is an autologous EBV-specific T cell therapy designed to selectively target EBV-infected tumor cells. The therapy is being investigated for its potential to reduce relapse risk and improve clinical outcomes in patients with NK/T-cell lymphoma. Detailed clinical data from the Phase 2 study will be presented at the ASCO (Free ASCO Whitepaper) Annual Meeting 2026.

(Press release, ViGenCell, APR 21, 2026, View Source [SID1234664632])

On April 21, 2026 Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, reported a poster presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which is being held from May 29 to June 2, 2026, at the McCormick Place in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will detail safety, pharmacokinetics, pharmacodynamics and antitumor activities of FL115 from the first-in-human FL115-101 study conducted at 3 investigational sites in US. First patient was dosed in December 2023, and the study was completed in September 2025 with total of 11 patients treated. One patient received the 1st dose in Jul 2024, remained progression-free at the study completion, and afterwards has continued to receive FL115 treatment under a Single Patient IND Protocol/Treatment Plan.

Details of the poster presentation are as follows:

Poster Board: 291
Poster Title: Safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activities of FL115, a novel IL-15 superagonist, from the first-in-human study in patients with locally advanced/metastatic solid tumors.
Session Type/Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT
About FL115

FL115 is an engineered IL-15/IL15Rα-Fbody fusion protein, aiming to enhance anti-tumor immunity via IL-15-mediated signaling on NK and CD8+ T cells while minimizing complexity from Fc. FL115 has demonstrated significant anti-tumor activities as a monotherapy or as part of combination therapy in vivo, and can be manufactured by a robust and efficient process with excellent product stability. Clinically, FL115 has demonstrated favorable safety profile and preliminary clinical responses as a monotherapy, and has the best-in-class potential to synergize with current and emerging T cell-targeting immunotherapies through combination therapy to significantly improve the treatment outcome for patients. It is currently being investigated in combination with Bacillus Calmette-Guérin (BCG) in a Phase 2 clinical trial to evaluate safety and preliminary efficacy in patients with nonmuscle invasive bladder cancer (NMIBC) and in combination with an anti-PD1 monoclonal antibody in a Phase 1b/2 clinical trial to evaluate safety and preliminary efficacy in patients with advanced solid tumors.

(Press release, Forlong Biotechnology, APR 21, 2026, View Source [SID1234664648])

On April 21, 2026 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), reported a poster will be presented at ASCO (Free ASCO Whitepaper) 2026 highlighting Phase 1 data for SIM0505 in the treatment of solid tumors. ASCO (Free ASCO Whitepaper) 2026 is being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to announce that the Phase 1 results for SIM0505 have been accepted as a poster presentation at ASCO (Free ASCO Whitepaper) 2026. This important milestone validates our collaborative clinical approach and highlights our mission of advancing innovative medicines to treat cancer patients," said Michael Richman, President and CEO of NextCure.

Presentation Details:

Title: Phase 1, multicenter, first-in-human (FIH) global study of SIM0505, an anti-CDH6 (CDH6) antibody-drug-conjugate (ADC) in patients with advanced solid tumors
Poster Abstract #: 5580
Poster Board: 246
Presenter: Xiaohua Wu, MD, PhD, Chief Physician and Chairman of the Multidisciplinary Team in Gynecologic Oncology at Fudan University Shanghai Cancer Center, Shanghai, China
Session: Gynecologic Cancer
Session Date: Monday June 1, 2026
Session Time: 9:00 AM CST to 12:00 PM CDT
A full copy of the poster will be available on the NextCure website under the Investor Relations "Events & Presentations" tab following the presentation.

About SIM0505

SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.

(Press release, NextCure, APR 21, 2026, View Source [SID1234664664])

On April 21, 2026, Hepion Pharmaceuticals, Inc. (the "Company") reported to have entered into securities purchase agreements (the "Agreements") with certain accredited investors (the "Investors") pursuant to which the Company agreed to sell and issue to the Investors in a private placement offering (the "Offering"), an aggregate offering of 17,500,000 shares of common stock, par value $0.0001 per share (the "Common Stock") at an offering price of $0.04 per share for gross proceeds of $700,000. The Offering closed on April 21, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Common Stock is being offered in reliance upon the exemption from the registration requirement of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws. The issuance of the Common Stock has not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.

The Agreements contain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions.

(Filing, Hepion Pharmaceuticals, APR 21, 2026, View Source [SID1234664681])